Agios' sickle cell trial falls short as drug doesn't appear to help patient pain crises

Agios Pharmaceuticals’ drug Pyrukynd hit only one of the two primary endpoints in its pivotal trial in sickle cell disease, the company said Wednesday, a significant setback for the company's plans ...